Odyssey Therapeutics, led by Gary Glick, has officially entered the public markets, marking a significant milestone for the Boston-based biotechnology company. The move comes after the company postponed its initial public offering (IPO) plans last year. With this IPO, Odyssey Therapeutics becomes the latest in a series of biotech firms in the region to go…
Generate Biomedicines, a Somerville-based company specializing in AI-driven drug development, has completed a $400 million initial public offering (IPO). The offering matches the record for the largest biotech IPO set in 2020, signaling renewed activity in the sector after a period of limited public offerings. The company’s successful entry into the public markets is being…
